Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
04 janv. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final...
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
03 janv. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 déc. 2023 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
18 déc. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as...
Ultragenyx anuncia la aprobación de Crysvita® (burosumab) en México para el tratamiento de adultos que viven con hipofosfatemia ligada al cromosoma X (XLH)
11 déc. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en el desarrollo de productos novedosos para...
Ultragenyx to Participate at Investor Conferences in November
20 nov. 2023 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
6th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) --...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 nov. 2023 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate in the Jefferies London Healthcare Conference
07 nov. 2023 17h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)
06 nov. 2023 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie...